Cannabis-based medicine is already bringing relief to many with more potential ahead.
News & Analysis: GW Pharmaceuticals
Levi Strauss and GW Pharmaceuticals really took it on the chin from investors.
Investors pared back some of the stock's recent gains as optimism faded in the wider marijuana niche.
Meanwhile, eight other marijuana stocks have lost their status as billion-dollar companies.
Approval in Europe for its cannabidiol-based drug will give the company another lucrative market to tap into.
The SAFE Banking Act moves forward, and Canopy Growth stock is now a neutral, according to Bank of America.
The EU's pharmaceuticals regulator gives Epidyolex the green light for helping treat seizures in children who suffer from two forms of severe epilepsy.
Exact Sciences and GW Pharmaceuticals received regulatory approvals that will allow the companies to expand sales of successful products.
Legal cannabis revenues haven't been expanding nearly as fast in Canada as analysts had forecast. But there are greater opportunities elsewhere.
It appears that the U.S. Drug Enforcement Agency is finally getting serious about marijuana.